Scenarios that move GALT

Galectin Therapeutics Inc. - Common Stock

Scenarios that move GALT: 1 analysis, 1 positive, 0 negative.

1. 2026-10-14 · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▲ · impact +35 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing